# Doxorubicin

## Lipo-Dox inj 20mg (自費用)

| 藥物代碼           | ILIPD                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa, skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.                                      |
| 副作用             | Infusion-associated acute reactions, stomatitis, Palmar-plantar erythrodysesthesia, cardiac toxicity. Nausea, leukopenia, neutropenia, anemia & thrombocytopenia. Asthenia, alopecia, fever, diarrhea. Resp infections, laboratory abnormalities.                                                                                                                                                                                                      |
| 禁忌               | Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal, conventional doxorubicin, or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon                                                                                                                                                                                                                        |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 用法用量           | Breast/Ovarian cancer 50 mg/m2 by IV infusion once every 4 weeks. AIDS-related Kaposi's sarcoma 20 mg/m2 by IV infusion every 2-3 weeks.                                                                                                                                                                                                                                                                                                               |
| 肝功能異常         | 需 調 整 劑 量  Bilirubin 1.2-3 mg/dL: Initial dose: Reduce dose to 75% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes, may increase to full dose with cycle 2 Bilirubin >3 mg/dL: Initial dose: Reduce dose to 50% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes, may increase dose to 75% of normal dose for cycle 2; if cycle 2 dose tolerated, may increase to full dose for subsequent cycles. |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 孕期用藥建議       | Contraindicated - 1st trimester                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期用藥建議     | Contraindicated 哺乳期使用禁忌                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 輸注點滴液         | 【D5W】 仿單建議                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IVD 用法建議       | 給藥劑量在90mg以下：以250 ml之5%葡萄糖溶液(Dextrose 5% in Water)稀釋 給藥劑量在90mg(含)以上：以500 ml之5%葡萄糖溶液稀釋。 起始劑量的輸注速率應不超過1 mg/min。若無輸注不良反應，剩餘藥物可以60分鐘輸注完畢。                                                                                                                                                                                                                                           |
| 注意事項           | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。                                                                                                                                                                                                                                                                                                                                                   |

## Lipo-Dox inj 20mg (健保用)

| 藥物代碼           | ILIPD1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa, skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 副作用             | Infusion-associated acute reactions, stomatitis, Palmar-plantar erythrodysesthesia, cardiac toxicity. Nausea, leukopenia, neutropenia, anemia & thrombocytopenia. Asthenia, alopecia, fever, diarrhea. Resp infections, laboratory abnormalities.Dermatologic: Alopecia, Hand-foot syndrome due to cytotoxic therapy (ovarian cancer, 50.6% AIDS-related Kaposi's sarcoma, 3.4% multiple myeloma, 19% ), Rash (ovarian cancer, 28.5%AIDS-related Kaposi's sarcoma, 1% to 5% multiple myeloma, 22% )Gastrointestinal: Constipation (multiple myeloma, 31% ), Diarrhea (ovarian cancer, 20.9%AIDS-related Kaposi's sarcoma, 7.8%multiple myeloma, 46% ), Loss of appetite (ovarian cancer, 20.1% AIDS-related Kaposi's sarcoma, 1% to 5%multiple myeloma, 19% ), Nausea (ovarian cancer, 46% AIDS-related Kaposi's sarcoma, 16.9%multiple myeloma, 48% ), Stomatitis (ovarian cancer, 41.4% AIDS-related Kaposi's sarcoma, 6.8%multiple myeloma, 20% ), Vomiting (ovarian cancer, 32.6%AIDS-related Kaposi's sarcoma, 7.8%multiple myeloma, 32%)Hematologic: Decreased platelet count (ovarian cancer, 13% to 24.2%; AIDS-related Kaposi's sarcoma, 60.9%; multiple myeloma, 33%), Hemoglobin low (ovarian cancer, 40.2% to 52.6%; AIDS-related Kaposi's sarcoma, 55.4%; multiple myeloma, 25% ), Neutrophil count abnormal (ovarian cancer, 19% to 35.1%; AIDS-related Kaposi's sarcoma, 48.9%; multiple myeloma, 36%)Neurologic: Asthenia (ovarian cancer, 40.2% AIDS-related Kaposi's sarcoma, 9.9% multiple myeloma, 22% )Psychiatric: Fatigue (multiple myeloma, 36%; )Other: Drug fever (ovarian cancer, 21.3%AIDS-related Kaposi's sarcoma, 9.1%multiple myeloma, 31% ) |
| 禁忌               | Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal, conventional doxorubicin, or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 藥物保存方式       | 2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 用法用量           | Breast/Ovarian cancer 50 mg/m2 by IV infusion once every 4 weeks. AIDS-related Kaposi's sarcoma 20 mg/m2 by IV infusion every 2-3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 肝功能異常         | 需 調 整 劑 量  如果膽紅素值介於1.2-3.0mg/dl，第一次給藥劑量應降低25%；如果膽紅素值大於3.0mg/dl 第一次給藥劑量應降低50%。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 懷孕用藥危分級     | 儘量避免                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 孕期用藥建議       | Contraindicated - 1st trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 哺乳期用藥建議     | Contraindicated 哺乳期使用禁忌                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 注意事項           | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。 3.Pegylatedliposomal doxorubicin的累計劑量到450mg/m2時,需作左心室功能評估,並且在每增加100mg/m2給藥前再次評估. 450-600mg/m2並不會增加心臟毒性的危險性.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

